title: Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
authors.affiliation: Hospital Ramón y Cajal, Servicio de Dermatología, Madrid, Spain. letticiaac@gmail.com
authors.forename: Leticia
authors.initials: L
authors.lastname: Alonso-Castro
authors.forename: Luis
authors.initials: L
authors.lastname: Ríos-Buceta
authors.forename: Sergio
authors.initials: S
authors.lastname: Vano-Galvan
authors.forename: Carmen
authors.initials: C
authors.lastname: Moreno
authors.forename: Ainara
authors.initials: A
authors.lastname: Soria-Rivas
authors.forename: Pedro
authors.initials: P
authors.lastname: Jaén
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D012880:Skin Pigmentation / Q000187:drug effects; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib; D014820:Vitiligo / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib